What is Circassia?
Established in 2006 and headquartered in Oxford, UK, Circassia is dedicated to advancing the diagnosis and management of asthma. The company operates within the specialized field of respiratory health, aiming to provide innovative solutions for patients and healthcare providers. Its focus on asthma positions it within a critical segment of the broader healthcare and biotechnology industry, where advancements in diagnostics and treatment are highly valued.
How much funding has Circassia raised?
Circassia has raised a total of $667.3M across 7 funding rounds:
Series A
$7.5M
Series B
$21.8M
Series C
$25M
Series D
$98M
Series E
$19M
Other Financing Round
$154M
Stock Offering
$342M
Series A (2007): $7.5M with participation from Undisclosed
Series B (2008): $21.8M led by Goldman Sachs, Invesco, Imperial Innovations, and Lansdowne Partners
Series C (2009): $25M supported by Invesco, Lansdowne Partners, and Imperial Innovations
Series D (2011): $98M featuring Invesco and Imperial Innovations
Series E (2012): $19M backed by Imperial Innovations and Invesco
Other Financing Round (2012): $154M with participation from Invesco and Imperial Innovations
Stock Issuance/Offering (2015): $342M led by Undisclosed
Key Investors in Circassia
Invesco
Invesco is a global investment management firm providing a wide range of financial services to institutional and retail clients. It manages diverse portfolios across equity, fixed income, and alternative markets.
Imperial Innovations
Imperial Innovations, linked to Imperial College London, focuses on commercializing technologies developed by the university's researchers. It supports innovation in science, engineering, business, and medicine.
Lansdowne Partners
Lansdowne Partners is an investment management partnership established in 1998, aiming to deliver superior long-term investment returns and client service.
What's next for Circassia?
The recent strategic investment signifies a pivotal moment for Circassia, likely indicating a transition into a scaling phase. This capital injection will empower the company to accelerate its product development pipeline, enhance its market penetration strategies, and potentially explore new therapeutic areas or diagnostic technologies. The sustained backing from investors suggests confidence in Circassia's long-term vision and its capacity to deliver impactful solutions in the respiratory health market.
See full Circassia company page
